Department of Biomaterials Science, College of Natural Resources & Life Science, Pusan National University/Life and Industry Convergence Research Institute, Miryang 627-706, Korea.
BMC Complement Altern Med. 2013 Nov 26;13:333. doi: 10.1186/1472-6882-13-333.
Liriope platyphylla has long been reported as a therapeutic drug for treatment of various human chronic diseases including inflammation, diabetes, neurodegenerative disorders, obesity, and atopic dermatitis. To investigate the laxative effects of L. platyphylla, alterations in excretion parameters, histological structure, mucin secretion, and related protein levels were investigated in rats with loperamide (Lop)-induced constipation after treatment with aqueous extract of L. platyphylla (AEtLP).
Alterations on constipation phenotypes were measured in rats with Lop-induced constipation after treatment with AEtLP using excretion parameter analysis, histological analysis, RT-PCR, western blot and transmission electron microscope (TEM) analysis.
The amounts of stool and urine excretion were significantly higher in the Lop + AEtLP-treated group than in the Lop + vehicle-treated group, whereas food intake and water consumption were maintained at constant levels. AEtLP treatment also induced an increase in villus length, crypt layer, and muscle thickness in the constipation model. Total mucin secretion was higher in the Lop + AEtLP-treated group than in the Lop + vehicle-treated group, although mucin secretion per crypt was very similar among all groups. Furthermore, RT-PCR and western blot revealed a dramatic reduction of key factors level on the muscarinic acetylcholine receptors (mAChRs) signaling pathway in the Lop + AEtLP-treated group relative to the Lop + vehicle-treated group. Especially, the accumulation of lipid droplets in enterocytes of crypts following Lop treatment was improved to the level of the No-treated group in response to AEtLP treatment.
These results suggest that AEtLP improves constipation induced by Lop treatment through an increase in crypt layer and stimulation of lipid droplet secretions. These data are the first to show that the laxative effects of AEtLP are closely related to the down-regulation of mAchRs and their downstream signals.
山麦冬长期以来一直被报道为治疗各种人类慢性疾病的治疗药物，包括炎症、糖尿病、神经退行性疾病、肥胖症和特应性皮炎。为了研究山麦冬的通便作用，在给予山麦冬水提物（AEtLP）后，观察洛哌丁胺（Lop）诱导的便秘大鼠的排泄参数、组织学结构、粘蛋白分泌和相关蛋白水平的变化。
采用排泄参数分析、组织学分析、RT-PCR、western blot 和透射电镜（TEM）分析，观察 Lop 诱导的便秘大鼠给予 AEtLP 后的便秘表型变化。
与 Lop+vehicle 组相比，Lop+AEtLP 组大鼠的粪便和尿液排泄量明显增加，而食物摄入和水消耗保持在恒定水平。AEtLP 治疗还诱导便秘模型中绒毛长度、隐窝层和肌肉厚度增加。Lop+AEtLP 组大鼠总粘蛋白分泌量高于 Lop+vehicle 组，但各组隐窝粘蛋白分泌量非常相似。此外，RT-PCR 和 western blot 显示，与 Lop+vehicle 组相比，Lop+AEtLP 组 M 乙酰胆碱受体（mAChR）信号通路的关键因子水平明显降低。特别是，AEtLP 治疗可改善 Lop 处理后隐窝中肠细胞内脂滴的积累，使其恢复至未处理组水平。
这些结果表明，AEtLP 通过增加隐窝层和刺激脂滴分泌来改善 Lop 诱导的便秘。这些数据首次表明，AEtLP 的通便作用与 mAchR 及其下游信号的下调密切相关。
Zotero 插件
